The cardiovascular (CV) benefits of the SGLT2* inhibitor dapagliflozin extend across a broad spectrum of patients with type 2 diabetes (T2D) and high CV risk, in particular those with heart failure with reduced ejection fraction (HFrEF), reports a subanalysis of the DECLARE-TIMI 58 trial presented at ACC.19 Annual Scientific Session.
Administering intravenous magnesium sulphate to patients following acute stroke does not help improve global and functional outcomes, as well as survival, at 90 days after the index episode, according to the results of a meta-analysis.
Performing computed tomography (CT) scans prior to cancer treatment can provide information about coronary artery calcification (CAC), a risk marker for cardiovascular disease (CVD), but this evidence is not always reported and rarely acted upon clinically, according to a study presented at the American College of Cardiology’s 68th Annual Scientific Session (ACC 2019).
Early, in-hospital initiation of sacubitril/valsartan appeared to be a better strategy than enalapril switched to sacubitril/valsartan 8 weeks after randomization in patients with acute decompensated heart failure with reduced ejection fraction (HFrEF), the 4-week, open-label PIONEER-HF extension study has shown.
Implantation of a CardioMEMS-HF* device, an ambulatory haemodynamic monitor with an implantable pulmonary artery pressure (PAP) sensor, led to a reduction in hospital admissions among patients with HF, according to results of the CardioMEMS** study presented at ACC.19.
Proprotein convertase sutilisin/kexin 9 (PCSK9) inhibitors appear to improve cardiovascular (CV) outcomes, significantly reducing the risks of major adverse cardiovascular events, nonfatal myocardial infarction and stroke, according to a meta-analysis.
Patients with heart failure with preserved ejection fraction (HFpEF) and evidence of pulmonary vascular disease (PVD) may benefit from targeted therapy with phosphodiesterase type 5 inhibitor (PDE5i), a recent study has found.